Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Curr Mol Biol Rep. 2020 Oct 24;6(4):161–172. doi: 10.1007/s40610-020-00140-1

Figure 1. Senolytics Clinical Trials in Humans.

Figure 1.

Shown are some completed, recruiting, ongoing and planned trials. Before being tested in healthy adults for delaying or alleviating aging-related diseases and syndromes, senolytics are being tested for safety and efficacy of removing senescent cells from patients with serious conditions involving senescent cell accumulation for which there are currently no other cures. These include idiopathic pulmonary fibrosis (IPF), diabetic/chronic kidney disease, tau+ Alzheimer’s disease, accelerated aging resulting from hematopoietic stem cell transplantation, frailty and osteoarthritis. Some completed Phase I trials have reported no serious adverse effects (eg, D+Q, UBX0101) and are moving on to Phase II trials. (Image created using Biorender.)